Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trialEugenia Abaleke, Emmanuel O Adewunmi, Ashraf Omar Abdelaziz et al.|The Lancet|2021Cited by 564
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trialNatalie Staplin, Vicki Adell, Richard Haynes et al.|The Lancet Diabetes & Endocrinology|2023Cited by 94